| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
16,699,000 |
| Market
Cap: |
296.24(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$9.99 - $31.5 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 15.9 |
| Insider 3/6 Months : 16.5 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Calyxt is a plant-based synthetic biology company that utilizes its proprietary PlantSpring™ technology platform to engineer plant metabolism to produce plant-based chemistries for use in customers' materials and products. Co. is focused on developing these synthetic biology solutions for customers in differentiated end markets, including the cosmeceutical, nutraceutical, and pharmaceutical industries. Co. also out-licenses elements of the PlantSpring technology platform and may selectively develop products for customers in agriculture. Co.'s product, an improved digestibility alfalfa, was developed with and licensed to S&W Seed Company.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
517,107 |
518,107 |
518,107 |
| Total Buy Value |
$0 |
$5,470,992 |
$5,502,492 |
$5,502,492 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
1 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
30,000 |
| Total Sell Value |
$0 |
$0 |
$0 |
$7,173 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ribeill Yves J |
Director |
• • – |
2019-03-14 |
4 |
S |
$16.33 |
$81,317 |
D/D |
(4,980) |
40,020 |
|
- |
|
| Ribeill Yves J |
Director |
• • – |
2019-03-13 |
4 |
S |
$16.08 |
$80,410 |
D/D |
(5,000) |
45,000 |
|
- |
|
| Ribeill Yves J |
Director |
• • – |
2019-03-12 |
4 |
S |
$16.76 |
$83,819 |
D/D |
(5,000) |
50,000 |
|
- |
|
| Blome James |
Chief Executive Officer |
• • – |
2019-03-12 |
4 |
S |
$16.58 |
$42,802 |
D/D |
(2,582) |
161,882 |
|
- |
|
| Ribeill Yves J |
Director |
• • – |
2019-03-11 |
4 |
S |
$17.39 |
$86,958 |
D/D |
(5,000) |
55,000 |
|
- |
|
| Voytas Daniel F |
Chief Science Officer |
• • – |
2019-02-25 |
4 |
AS |
$16.00 |
$63,632 |
D/D |
(3,977) |
92,982 |
|
- |
|
| Voytas Daniel F |
Chief Science Officer |
• • – |
2019-02-25 |
4 |
OE |
$3.59 |
$14,277 |
D/D |
3,977 |
96,959 |
|
- |
|
| Voytas Daniel F |
Chief Science Officer |
• • – |
2019-02-01 |
4 |
AS |
$13.00 |
$53,131 |
D/D |
(4,087) |
92,982 |
|
- |
|
| Voytas Daniel F |
Chief Science Officer |
• • – |
2019-02-01 |
4 |
OE |
$3.71 |
$15,180 |
D/D |
4,087 |
97,069 |
|
- |
|
| Voytas Daniel F |
Chief Science Officer |
• • – |
2019-01-31 |
4 |
AS |
$13.00 |
$53,079 |
D/D |
(4,083) |
92,982 |
|
- |
|
| Voytas Daniel F |
Chief Science Officer |
• • – |
2019-01-31 |
4 |
OE |
$3.71 |
$15,165 |
D/D |
4,083 |
97,065 |
|
- |
|
| Dumont Philippe |
Director |
• • – |
2019-01-04 |
4 |
AS |
$12.00 |
$13,404 |
D/D |
(1,117) |
17,060 |
|
- |
|
| Sahoo Manoj |
Chief Commercial Officer |
• • – |
2019-01-02 |
4 |
AS |
$10.39 |
$25,389 |
D/D |
(2,444) |
76,669 |
|
- |
|
| Voytas Daniel F |
Chief Science Officer |
• • – |
2018-12-18 |
4 |
AS |
$13.00 |
$53,079 |
D/D |
(4,083) |
92,982 |
|
- |
|
| Voytas Daniel F |
Chief Science Officer |
• • – |
2018-12-18 |
4 |
OE |
$3.71 |
$15,165 |
D/D |
4,083 |
97,065 |
|
- |
|
| Voytas Daniel F |
Chief Science Officer |
• • – |
2018-11-08 |
4 |
AS |
$13.00 |
$53,079 |
D/D |
(4,083) |
92,982 |
|
- |
|
| Voytas Daniel F |
Chief Science Officer |
• • – |
2018-11-08 |
4 |
OE |
$3.71 |
$15,165 |
D/D |
4,083 |
97,065 |
|
- |
|
| Voytas Daniel F |
Chief Science Officer |
• • – |
2018-10-09 |
4 |
AS |
$13.84 |
$56,514 |
D/D |
(4,083) |
92,982 |
|
- |
|
| Voytas Daniel F |
Chief Science Officer |
• • – |
2018-10-09 |
4 |
OE |
$3.71 |
$15,165 |
D/D |
4,083 |
97,065 |
|
- |
|
| Jonathan Fassberg |
Director |
• • – |
2018-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
19,600 |
19,600 |
|
- |
|
| Neugent Christopher J |
Director |
• • – |
2018-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
19,600 |
19,600 |
|
- |
|
| Dumont Philippe |
Director |
• • – |
2018-10-05 |
4 |
AS |
$14.11 |
$15,765 |
D/D |
(1,117) |
18,177 |
|
- |
|
| Sahoo Manoj |
Chief Commercial Officer |
• • – |
2018-10-01 |
4 |
AS |
$14.84 |
$37,416 |
D/D |
(2,521) |
79,113 |
|
- |
|
| Voytas Daniel F |
Chief Science Officer |
• • – |
2018-09-20 |
4 |
AS |
$16.00 |
$74,656 |
D/D |
(4,666) |
92,982 |
|
- |
|
| Voytas Daniel F |
Chief Science Officer |
• • – |
2018-09-20 |
4 |
OE |
$3.59 |
$16,751 |
D/D |
4,666 |
97,648 |
|
- |
|
223 Records found
|
|
Page 6 of 9 |
|
|
0.11 (0.62%) 
